SCHEMBL410147

SCHEMBL410147

OC(CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 1.00
MAPT P10636 6/20 0.57
KMT2A Q03164 3/20 0.57
HTT P42858 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 2/20 0.54
RAD52 P43351 1/20 0.54
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 1/20 0.53
P2RX3 P56373 1/20 0.52
TP53 P04637 2/20 0.52
MAPK1 P28482 2/20 0.52
LMNA P02545 1/20 0.52
TSPO P30536 1/20 0.52
BAX Q07812 1/20 0.51
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391692 1.00 DNM1 (1.00) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL29351340 1.00 DNM1 (1.00) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL20334192 0.94 DNM1 (0.88) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL410692 0.92 DNM1 (0.85) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL30897301 0.90 DNM1 (0.80) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL28626877 0.90 DNM1 (0.80) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL407045 0.90 DNM1 (0.80) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL14689975 0.90 DNM1 (0.80) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL16923522 0.88 DNM1 (0.77) DNM1MAPTKMT2AHTTNPSR1
SCHEMBL28635462 0.88 DNM1 (0.77) DNM1MAPTKMT2AHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190218203-A1 Neuroprotective Compounds and Use Thereof UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2019-07-18 US claimed
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
EP-2590647-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2017-11-08 EP claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160272619-A1 Neuroprotective Compounds and Use Thereof UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2016-09-22 US claimed
EP-3068388-A2 NEUROPROTECTIVE COMPOUNDS AND USE THEREOF Board of Regents of the University of Texas System (US) 2016-09-21 EP claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
WO-2015070234-A9 NEUROPROTECTIVE COMPOUNDS AND USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-12-10 WO claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 1086/4885MAPT 578/4885KMT2A 3075/4885
US-20190218203-A1 Neuroprotective Compounds and Use Thereof NLN, GAP43, BDNF DNM1 1332/4885MAPT 42/4885KMT2A 4445/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX DNM1 897/4885MAPT 136/4885KMT2A 3749/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885MAPT 559/4885KMT2A 2693/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885MAPT 136/4885KMT2A 3749/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885MAPT 559/4885KMT2A 2693/4885
US-20160272619-A1 Neuroprotective Compounds and Use Thereof NLN, BDNF, CASP3 DNM1 1566/4885MAPT 185/4885KMT2A 4509/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885MAPT 136/4885KMT2A 3749/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 538/4885MAPT 571/4885KMT2A 2838/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885MAPT 559/4885KMT2A 2693/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885MAPT 142/4885KMT2A 3598/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885MAPT 142/4885KMT2A 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.